Alzheimers & Dementia

Papers
(The H4-Index of Alzheimers & Dementia is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats2380
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease1771
Prediction of amyloid‐beta accumulating normal cognitive elderly1232
Lean mass, grip strength, and hospital‐associated disability among older adults in Health ABC1156
Locus coeruleus hyperactivity in middle age may be associated with better cognitive performance599
MRI‐guided Clustering of Alzheimer’s Disease patients: A post‐hoc analysis of Phase 3 Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease417
Tracing synaptic loss in Alzheimer's brain with SV2A PET‐tracer UCB‐J333
Estimated pulse wave velocity associated with cognitive phenotypes in a rural older population in China: A cohort study326
Trajectories of Neurological Recovery 12 Months after Hospitalization for COVID‐19: A Prospective Longitudinal Study275
HbA1c variability associated with dementia risk in people with type 2 diabetes201
Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype?195
Evaluation of major national dementia policies and health‐care system preparedness for early medical action and implementation179
Education, neighborhood environment, and cognitive decline: Findings from two prospective cohort studies of older adults in China176
Impaired glymphatic function as a biomarker for subjective cognitive decline: An exploratory dual cohort study170
Trajectories of cognitive decline and dementia development: A 12‐year longitudinal study163
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study162
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)157
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy151
The Global Neurodegeneration Proteomics Consortium ‐ Biomarker and Drug Target Discovery Across >40,000 Biosamples for AD, PD, ALS, FTD, and Aging146
The Design of SPRINT MIND and SPRINT MIND 2020136
Rapid discovery and optimization of novel brain shuttles and shuttle‐enabled anti‐amyloid therapeutics using multiplexed in vivo biologics design133
Survey on knowledge of Uruguayan neurologist about the FINGER intervention133
Approach for developing interpretative cut‐points during implementation of a plasma p‐tau217 assay in the clinical laboratory124
Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease122
The power of cognitive rehabilitation in Alzheimer’s disease ‐A Systematic review and meta analysis112
Exploring Alzheimer’s disease progression through the lens of genetics and sleep disturbances112
Examining the impact of hormone therapy and Alzheimer’s disease risk factors on depressive symptoms in the Harvard Aging Brain Study109
Relationship between perivascular spaces and white matter hyperintensities in Alzheimer’s disease106
Social Engagement as a Protective Factor for Cognition in Older Adults: Examining Sex and Race Differences103
The Types and Consistency of Participant‐Specified Proxies During SPRINT97
Neural flexibility as a promising biomarker for Alzheimer’s Disease97
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease94
Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT)87
Mendelian randomization highlights causal association between genetically increased C‐reactive protein levels and reduced Alzheimer's disease risk84
Social frailty and the incidence of motoric cognitive risk syndrome in older adults84
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease79
Longitudinal multicenter head‐to‐head harmonization of tau‐PET tracers: an overview of the HEAD study cohort79
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium78
An international core outcome set for primary progressive aphasia (COS‐PPA): Consensus‐based recommendations for communication interventions across research and clinical settings78
Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial77
Intracranial arteriosclerosis and the risk of dementia: A population‐based cohort study76
Association of air quality reduction with incident dementia: Effects of natural course and hypothetical air pollutant interventions using g‐computation76
The use of the Cognitive Change Questionnaire by community health workers as dementia screening method74
The impact of the COVID‐19 pandemic on cognitive health72
Fish intake and MRI burden of cerebrovascular disease in older adults72
Association of neighborhood socioeconomic disadvantage and cognitive decline71
Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)71
The effect of prolonged lockdown due to COVID‐19 on demented patients of different stages and on their caregivers71
Assessing sex differences between mid‐life cardiovascular conditions or risk factors and mid‐life cognition decline70
The dementia policies in Australia relating to the COVID‐19 pandemic70
Policy recommendations from the perspective of health professionals who work with people with dementia in public tertiary hospitals in China69
The association between diabetes and Alzheimer’s disease pathophysiology69
Trajectories of self‐rated concerns in individuals developing cognitive decline68
Iron intake, brain iron, and Alzheimer’s disease among community‐dwelling older adults68
Outreach and recruitment of African Americans for Alzheimer’s disease studies during the COVID‐19 pandemic68
The troubles and needs of family caregivers of older adults with moderate to severe dementia67
Speed of cognitive decline in biomarker stratified SCD subgroups66
Feasibility of the occupational therapy protocol TAP (Tailored Activity Program) for the management of behaviors in a dementia hospital unit: Preliminary results from a pilot study66
Automating the verbal paired associates test to assess memory remotely and at scale65
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline65
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum65
Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J65
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen65
0.53417706489563